Dexcom CGM Trial Shows A1C Improvement in Non-Insulin Type 2 Diabetes
Dexcom announced that its CONNECT randomized controlled trial has been published in the New England Journal of Medicine. The study evaluated continuous glucose monitoring in adults with Type 2 diabetes who do not use insulin. Participants using the Dexcom G7 sensor achieved an average A1C reduction of 1.6 percentage points from a baseline of 8.8%.
Dexcom reported that its CONNECT study, a randomized controlled trial, has appeared in the New England Journal of Medicine. The research examined continuous glucose monitoring in adults with Type 2 diabetes who do not use insulin.
In that trial, people who wore the Dexcom G7 continuous glucose monitor saw their A1C fall by an average of 1.6 percentage points. Their starting average A1C was 8.8%, according to the company.
If these findings hold, adults with Type 2 diabetes who do not take insulin could have another tool for tracking glucose and potentially improving long-term control. Better A1C levels may reduce risks of diabetes-related complications, though individual results can vary. Wider use of CGM in this group could affect patients, clinicians, and payers as they weigh costs, access, and follow-up care. The trial’s publication may encourage more discussions about monitoring options beyond insulin-treated diabetes.